Dihydroergotamine Mesylate Patent Expiration
Dihydroergotamine Mesylate is used for acute treatment of migraine with or without aura. It was first introduced by Bausch Health Us Llc
Dihydroergotamine Mesylate Patents
Given below is the list of patents protecting Dihydroergotamine Mesylate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Atzumi | US11744967 | Intranasal delivery devices | Oct 12, 2041 | Satsuma Pharms |
| Atzumi | US12102754 | Intranasal delivery devices | Oct 12, 2041 | Satsuma Pharms |
| Atzumi | US10758532 | Compositions, devices, and methods for treating or preventing headaches | Dec 11, 2039 | Satsuma Pharms |
| Atzumi | US12263162 | Compositions, devices, and methods for treating or preventing headaches | Dec 11, 2039 | Satsuma Pharms |
| Brekiya (autoinjector) | US10532049 | Parenteral unit dosage form of dihydroergotamine | Feb 26, 2039 | Amneal |
| Brekiya (autoinjector) | US11304942 | Parenteral unit dosage form of dihydroergotamine | Feb 26, 2039 | Amneal |
| Brekiya (autoinjector) | US11819501 | Parenteral unit dosage form of dihydroergotamine | Feb 26, 2039 | Amneal |
| Trudhesa | US11185497 | Intranasal delivery of dihydroergotamine by precision olfactory device | Jan 04, 2039 | Impel Pharms |
| Atzumi | US10792253 | Pharmaceutical compositions | Aug 04, 2037 | Satsuma Pharms |
| Atzumi | US11872314 | Pharmaceutical compositions | Aug 04, 2037 | Satsuma Pharms |
| Trudhesa | US11266799 | In-line nasal delivery device | Nov 05, 2036 | Impel Pharms |
| Trudhesa | US9919117 | Nozzles for nasal drug delivery | Mar 17, 2033 | Impel Pharms |
| Trudhesa | US10940278 | Nozzles for nasal drug delivery | Jan 23, 2033 | Impel Pharms |
| Trudhesa | US10507295 | Nasal drug delivery device | Dec 25, 2032 | Impel Pharms |
| Trudhesa | US9550036 | Nasal drug delivery device | Sep 05, 2032 | Impel Pharms |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Dihydroergotamine Mesylate's patents.
Latest Legal Activities on Dihydroergotamine Mesylate's Patents
Given below is the list recent legal activities going on the following patents of Dihydroergotamine Mesylate.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Yr, Small Entity | 11 Jul, 2024 | US9550036 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 11 Jul, 2024 | US10940278 |
| Change in Power of Attorney (May Include Associate POA) Critical
| 02 Apr, 2024 | US11185497 |
| Email Notification Critical
| 02 Apr, 2024 | US11185497 |
| Change in Power of Attorney (May Include Associate POA) Critical
| 01 Apr, 2024 | US9550036 |
| Email Notification Critical
| 01 Apr, 2024 | US9550036 |
| Email Notification Critical
| 29 Mar, 2024 | US10940278 |
| Change in Power of Attorney (May Include Associate POA) Critical
| 29 Mar, 2024 | US10940278 |
| Email Notification Critical
| 28 Mar, 2024 | US11266799 |
| Change in Power of Attorney (May Include Associate POA) Critical
| 28 Mar, 2024 | US11266799 |
Dihydroergotamine Mesylate's Family Patents
